Aaron Kesselheim

Aaron Kesselheim MD JD MPH is an Associate Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital. Within the Division, Aaron created and leads the Program On Regulation, Therapeutics, And Law (PORTAL, www.PORTALresearch.org), an interdisciplinary research core focusing on intersections among prescription drugs and medical devices, patient health outcomes, and regulatory practices and the law. With 3 full-time faculty members, 5 post-docs, and numerous student affiliates, PORTAL is now among the largest, independent academic centers focusing on these issues in the country (Twitter: @PORTAL_research, @akesselheim). Since 2018, he serves as the co-director of the Harvard-MIT Center for Regulatory Science.

Author of over 350 publications in the peer-reviewed medical and health policy literatures, Aaron has testified before Congress on pharmaceutical policy, medical device regulation, generic drugs, and modernizing clinical trials, is a member of the FDA Peripheral and Central Nervous System Advisory Committee, and served on a National Academies of Science, Engineering and Medicine consensus committees on addressing the opioid epidemic and bioidentical hormone replacement. His work has been funded by the Greenwall Faculty Scholar in Bioethics Program, the Commonwealth Fund, the Robert Wood Johnson Foundation, Arnold Ventures, the Engelberg Foundation, the FDA, and AHRQ. Aaron is a core faculty member at the HMS Center for Bioethics, where he co-teaches a course on health policy, law, and bioethics and organizes a monthly policy and ethics seminar series. Aaron also serves as the Irving S. Ribicoff Visiting Associate Professor of Law at Yale Law School, where he teaches a yearly course on Food and Drug Administration Law. He recently developed a massive open online course called FDA and Prescription Drugs. He is the editor-in-chief of the Journal of Law, Medicine, and Ethics and is a member of the Perspectives advisory board for the New England Journal of Medicine.